Compare AXG & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AXG | AGMB |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | Hong Kong | Belgium |
| Employees | 33 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 712.4M | 677.9M |
| IPO Year | N/A | N/A |
| Metric | AXG | AGMB |
|---|---|---|
| Price | $3.66 | $11.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | ★ 329.2K | 137.3K |
| Earning Date | 01-09-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.53 | N/A |
| Revenue Next Year | $54.60 | $17.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.69 | $9.00 |
| 52 Week High | $4.75 | $17.45 |
| Indicator | AXG | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 47.42 | 54.88 |
| Support Level | $3.25 | $10.30 |
| Resistance Level | $3.90 | $12.21 |
| Average True Range (ATR) | 0.20 | 0.84 |
| MACD | 0.01 | 0.21 |
| Stochastic Oscillator | 27.91 | 68.15 |
Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.